Last reviewed · How we verify
Fenazoxine (NEFOPAM)
Fenazoxine (generic name: NEFOPAM) is a nefopam drug. It is currently FDA-approved.
Nefopam works by blocking the sodium-dependent serotonin transporter, which helps regulate pain perception in the brain.
Fenazoxine, also known as Nefopam, is a small molecule drug that targets the sodium-dependent serotonin transporter. It is classified as a nefopam drug class and has a bioavailability of 36%. The exact commercial status of Nefopam is unknown, but it is not FDA-approved for any indications. Nefopam has a half-life of 5.0 hours. Further information on its approved indications and patent status is not available.
At a glance
| Generic name | NEFOPAM |
|---|---|
| Drug class | nefopam |
| Target | 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
Imagine your brain has a 'pain filter' that helps decide how much pain to send to your body. Nefopam blocks this filter, making it harder for pain signals to get through and reducing the amount of pain you feel.
Approved indications
Common side effects
- Hepatocellular injury
- Cholestasis
- Drug reaction with eosinophilia and systemic symptoms
- Agranulocytosis
- Acute kidney injury
- Rash maculo-papular
- Hepatic cytolysis
- Acute generalised exanthematous pustulosis
- Confusional state
- Thrombocytopenia
- Toxic skin eruption
- Mixed liver injury
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (PHASE4)
- Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology (PHASE4)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Opioid Prescribing in the Emergency Department for Sickle Cell Disease
- Adjuvant Continuous Infusion of Nefopam Versus Standard of Care in Mechanically Ventilated Critically Ill Patients: Randomized Double-blind Controlled Study (PHASE3)
- Multimodal Analgesia Strategies After Major Shoulder Ambulatory Surgery (PHASE4)
- Regional Anesthesia by PENG-Block in Emergency Department (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fenazoxine CI brief — competitive landscape report
- Fenazoxine updates RSS · CI watch RSS
Frequently asked questions about Fenazoxine
What is Fenazoxine?
How does Fenazoxine work?
What is the generic name of Fenazoxine?
What drug class is Fenazoxine in?
What development phase is Fenazoxine in?
What are the side effects of Fenazoxine?
What does Fenazoxine target?
Related
- Drug class: All nefopam drugs
- Target: All drugs targeting 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing